Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Total Non-Current Liabilities (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $1.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Non-Current Liabilities rose 15.44% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Dec 2024, up 15.44%, and an annual FY2024 reading of $1.2 million, up 15.44% over the prior year.
  • Total Non-Current Liabilities was $1.2 million for Q4 2024 at BioRestorative Therapies, up from $1.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $17.7 million in Q1 2020 and bottomed at -$10.0 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $1.8 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities tumbled 410.69% in 2021, then surged 106.05% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $3.2 million in 2020, then crashed by 410.69% to -$10.0 million in 2021, then soared by 106.05% to $602619.0 in 2022, then surged by 76.46% to $1.1 million in 2023, then grew by 15.44% to $1.2 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for BRTX at $1.2 million in Q4 2024, $1.1 million in Q3 2024, and $827822.0 in Q2 2024.